tiprankstipranks
Trending News
More News >
Pfizer (PFE)
NYSE:PFE
US Market
Advertisement

Pfizer (PFE) Earnings Dates, Call Summary & Reports

Compare
34,661 Followers

Earnings Data

Report Date
Nov 04, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
0.71
Last Year’s EPS
1.06
Same Quarter Last Year
Moderate Buy
Based on 17 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with Pfizer showing strong financial performance, significant advancements in its R&D pipeline, and effective cost management. However, there are some challenges, particularly related to pricing pressures from the IRA Medicare Part D redesign and competitive pressures in the oncology sector.
Company Guidance
During Pfizer's Second Quarter 2025 Earnings Conference Call, the company provided several key metrics and updates on its performance and future guidance. CEO Albert Bourla highlighted Pfizer's strong performance, noting a 10% operational revenue increase to $14.7 billion and raising the adjusted diluted EPS guidance for the full year 2025. The company is actively engaging with policymakers to navigate geopolitical challenges while focusing on R&D productivity, commercial portfolio maximization, and expanding margins. Notable achievements include the progress of Elrexfio in multiple myeloma, with a median overall survival of over two years, and the potential of Sigvotatug Vedotin in non-small cell lung cancer, expected to impact a market projected to reach over $60 billion by 2030. CFO David Denton emphasized strategic financial management, reporting an adjusted EPS of $0.78 and highlighting cost management initiatives contributing to robust operating margins. Pfizer is also preparing for a Phase III start for its C. difficile vaccine candidate and advancing a Phase III program for a Lyme disease vaccine. The company continues to invest in its business, focusing on R&D and strategic partnerships, with a current business development capacity of approximately $13 billion. Overall, Pfizer remains committed to creating long-term shareholder value through disciplined execution and strategic investments.
Strong Year-to-Date Performance and Raised EPS Guidance
Pfizer raised its adjusted diluted EPS guidance for the full year 2025 due to strong year-to-date performance, indicating confidence in its financial outlook.
Significant R&D Advancements
Pfizer highlighted several promising developments in its R&D pipeline, including Elrexfio's notable performance in multiple myeloma and Sigvotatug Vedotin's potential in non-small cell lung cancer.
Strong Growth in Key Products
The Vyndaqel family saw a 21% year-over-year operational growth, and Padcev experienced a 38% operational growth, demonstrating robust demand for key products.
Cost Management and Operating Margins
Pfizer's cost optimization strategies led to an 8% decline in total adjusted operating expenses, contributing to improved operating margins.
Strategic Business Development Initiatives
Pfizer closed an in-licensing agreement with 3SBio, granting exclusive rights to develop and commercialize a promising bispecific antibody.

Pfizer (PFE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PFE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 04, 2025
2025 (Q3)
0.71 / -
1.06
Aug 06, 2025
2025 (Q2)
0.58 / 0.78
0.630.00% (+0.18)
Apr 29, 2025
2025 (Q1)
0.67 / 0.92
0.8212.20% (+0.10)
Feb 04, 2025
2024 (Q4)
0.47 / 0.63
0.1530.00% (+0.53)
Oct 29, 2024
2024 (Q3)
0.61 / 1.06
-0.17723.53% (+1.23)
Jul 30, 2024
2024 (Q2)
0.46 / 0.60
0.67-10.45% (-0.07)
May 01, 2024
2024 (Q1)
0.52 / 0.82
1.23-33.33% (-0.41)
Jan 30, 2024
2023 (Q4)
-0.16 / 0.10
1.14-91.23% (-1.04)
Oct 31, 2023
2023 (Q3)
-0.08 / -0.17
1.78-109.55% (-1.95)
Aug 01, 2023
2023 (Q2)
0.57 / 0.67
2.04-67.16% (-1.37)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PFE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 06, 2025
$24.75$23.93-3.31%
Apr 29, 2025
$22.23$22.95+3.24%
Feb 04, 2025
$25.27$24.96-1.23%
Oct 29, 2024
$26.97$26.59-1.41%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pfizer (PFE) report earnings?
Pfizer (PFE) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).
    What is Pfizer (PFE) earnings time?
    Pfizer (PFE) earnings time is at Nov 04, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PFE EPS forecast?
          PFE EPS forecast for the fiscal quarter 2025 (Q3) is 0.71.

            Pfizer (PFE) Earnings News

            PFE Earnings: Pfizer Stock Climbs on Strong Q2 and Upbeat Guidance
            Premium
            Market News
            PFE Earnings: Pfizer Stock Climbs on Strong Q2 and Upbeat Guidance
            28d ago
            MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
            Premium
            Market News
            MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
            1M ago
            PFE Earnings: Pfizer Stock Jumps on Q4 Beats
            Premium
            Market News
            PFE Earnings: Pfizer Stock Jumps on Q4 Beats
            7M ago
            BNTX Earnings: BioNTech Reports Better-than-Expected Q3 Earnings, Lowers Revenue Outlook
            Premium
            Market News
            BNTX Earnings: BioNTech Reports Better-than-Expected Q3 Earnings, Lowers Revenue Outlook
            10M ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis